Quarterly Statement Third Quarter of 2022 Bayer with continued strong performance // Group sales at €11.3 billion (Fx & p adj. + 5.7%) // EBITDA before special items rises significantly to €2.5 billion (+ 17.3%) // Crop Science achieves strong sales gains; sales also up at Pharmaceuticals and Consumer Health // All divisions report significant increase in earnings // Core earnings per share at €1.13 (+ 7.6%) // Net income at €0.5 billion // Free cash flow at €1.7 billion // Major progress in Pharmaceuticals ...